Genprex, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Genprex, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $2.24M, a 28.74% increase year-over-year.
- Genprex, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $13.36M, a 121.58% increase year-over-year.
- Genprex, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $1.74M.
- Genprex, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $6.03M.
- Genprex, Inc. stock issued during period, value, new issues for fiscal 2022 was $6.43K, a 99.97% decline from fiscal 2021.
- Genprex, Inc. stock issued during period, value, new issues for fiscal 2021 was $25.68M, a 38.26% decline from fiscal 2020.
- Genprex, Inc. stock issued during period, value, new issues for fiscal 2020 was $41.59M.
- Genprex, Inc. stock issued during period, value, new issues for fiscal 2018 was $15.39M, a 1838.30% increase from fiscal 2017.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $2.24M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $13.36M 10-Q · filed 2026-08-14 | |
| 2025-06-30 | $1.74M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $6.03M 10-Q · filed 2026-08-14 | |
| 2023-09-30 | $6.82M 10-Q · filed 2023-11-14 | |
| 2023-03-31 | $3.78M 10-Q · filed 2023-11-14 | |
| 2022-12-31 | $6.43K 10-K · filed 2024-04-01 | |
| 2022-09-30 | $1.75K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-21 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $25.68M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $243.55K 10-Q · filed 2022-11-14 | $64.73M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $110.03K 10-Q · filed 2022-11-14 | $65.28M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-03-31 | $25.32M 10-Q · filed 2022-11-14 | $67.74M derived: sum of 4 quarters · filed 2022-11-14 |
| 2020-12-31 | $39.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $41.59M 10-K · filed 2022-03-30 |
| 2020-09-30 | $793.53K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $2.57M 10-Q · filed 2021-11-15 | |
| 2020-03-31 | $25.73M 10-Q · filed 2021-11-15 | |
| 2019-03-31 | $200.00 10-Q/A · filed 2019-05-20 | |
| 2018-12-31 | $15.39M 10-K · filed 2019-04-01 | |
| 2018-06-30 | $15.39M 10-Q · filed 2019-08-13 | |
| 2017-12-31 | $793.97K 10-K · filed 2019-04-01 | |
| 2016-12-31 | $2.71M 10-K · filed 2018-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |